Class Period: April 30, 2021 to August 31, 2021
Lead Plaintiff Deadline: June 6, 2022
No obligation or cost to you.
Learn more about your recoverable losses in ABBV:
CLASS ACTION CASE DETAILS: The filed complaint alleges that AbbVie Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) safety concerns about Pfizer Inc.'s drug Xeljanz extended to Abbvie's drug Rinvoq and to other Janus kinase enzyme inhibitor drugs; (2) as a result, it was likely that the U.S. Food and Drug Administration would require additional safety warnings for Rinvoq and would delay the approval of additional treatment indications for Rinvoq; and (3) therefore, defendants' statements about the Company's business, operations, and prospects lacked a reasonable basis.
WHAT THIS MEANS TO YOU AS A SHAREHOLDER: If you have suffered a loss in AbbVie you have until June 6, 2022 to petition the court for lead plaintiff status. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
NO COST TO YOU: If you purchased AbbVie securities during the relevant period, you may be entitled to compensation without payment of any out-of-pocket fees.
HOW TO PROTECT YOUR FINANCIAL INTERESTS: For additional information about the ABBV lawsuit, please contact J. Klein, Esq. by telephone at 212-616-4899 or click this link: https://www.kleinstocklaw.com/pslra-1/abbvie-inc-loss-submission-form-2?id=25804&from=4 .
ABOUT KLEIN LAW FIRM
J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. The Klein Law Firm is a boutique litigation firm with experience in a wide range of areas including securities law, corporate finance and commercial litigation. Since 2011, our experienced attorneys have achieved superior results for our clients with a personalized focus. Attorney advertising. Prior results do not guarantee similar outcomes.
View original content: https://www.prnewswire.com/news-releases/abbv-alert-the-klein-law-firm-announces-a-lead-plaintiff-deadline-of-june-6-2022-in-the-class-action-filed-on-behalf-of-abbvie-inc-shareholders-301522777.html
SOURCE The Klein Law Firm